← Return to Good news, Bensocatib Trials Continue for Bronchieactasis

Discussion

Good news, Bensocatib Trials Continue for Bronchieactasis

MAC & Bronchiectasis | Last Active: Aug 20 1:10pm | Replies (24)
Comment receiving replies
@bsi15

this is probably what some top-experts are referring to
in a recent comment :

Chalmers,Goeminne,Ringshausen,
World Bronchiectasis Conference 2024,
This is a time of great progress and change in the field of bronchiectasis.
A new generation of anti-inflammatory therapies such as dipeptidyl
peptidase-1/cathepsin C
inhibitors are in advanced clinical development [2],

Jump to this post

Replies to "this is probably what some top-experts are referring to in a recent comment : Chalmers,Goeminne,Ringshausen, World..."
bsi15 | @bsi15 | Aug 20 1:10pm

Results showed that a 10 milligram dose of brensocatib
reduced the annualized rate of pulmonary exacerbations by
21.1% versus placebo, while a 25 milligram dose led to a 19.4% reduction.

breakthrough research
past 15 years.
significant reductions in pulmonary exacerbations
James Chalmers, "I am thrilled that the ASPEN ...
This is a great day for patients.”

looks like the typical advertisement exaggerations to me
just 20% fewer exacerbations - not a game-changer

so with BSI=15 my life expectancy goes up from
maybe 5 to 6 years
due to Brensocatib

VIEW AND REPLY